The influence of anxiety and depression on respiratory drug consumption in a general population sample (Abstract/Poster in convegno)

Type
Label
  • The influence of anxiety and depression on respiratory drug consumption in a general population sample (Abstract/Poster in convegno) (literal)
Anno
  • 2011-01-01T00:00:00+01:00 (literal)
Alternative label
  • G. Viegi, G. Sarno, S. Baldacci, S. Cerrai, S. Maio, M. Fresta, F. Martini, A. Angino, F. Di Pede, F. Cibella (2011)
    The influence of anxiety and depression on respiratory drug consumption in a general population sample
    in American thoracic society 2011 international conference, Denver, Colorado, May 13 - 18, 2011
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • G. Viegi, G. Sarno, S. Baldacci, S. Cerrai, S. Maio, M. Fresta, F. Martini, A. Angino, F. Di Pede, F. Cibella (literal)
Pagina inizio
  • A6356 (literal)
Pagina fine
  • A6356 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni
  • ID_PUMA: cnr.ifc/2011-A6-004 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url
  • http://ajrccm.atsjournals.org/content/vol183/1_MeetingAbstracts/index.dtl (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 183 (literal)
Rivista
Note
  • Poster (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • National Research Council, Palermo, Italy ; National Research Council, Pisa, Italy (literal)
Titolo
  • The influence of anxiety and depression on respiratory drug consumption in a general population sample (literal)
Abstract
  • Rationale: anxiety and depression are two common comorbidity in subjects with respiratory diseases. The present work is aimed at evaluating, in an Italian general population sample, the influence of anxiety/depression on respiratory drug consumption in subjects with asthma/COPD. Methods: within the European Union funded project IMCA2 (Indicators for Monitoring COPD and Asthma in the EU), a sample of subjects living in Pisa (Central Italy) was selected. An information technology tool allowed to record spirometry and to fill in a core questionnaire on socio-demographic characteristics, respiratory symptoms/diseases, risk factors and anxiety/depression. The Hospital Anxiety and Depression Scale (HADS) was used to obtain confirmation in the anxiety/depression diagnoses. Statistical analyses were performed using the statistical package SPSS 13.0. 'Asthma' is identified by having a previous medical diagnosis or wheezing/whistling, attacks of shortness of breath with wheezes and nocturnal attacks of shortness of breath. 'COPD' is identified by having a previous medical diagnosis of chronic bronchitis, emphysema or chronic cough, chronic phlegm and dyspnoea >= II level. A multinomial logistic regression analysis, adjusted for smoking habits, age, sex, medical examination, was run to assess association between respiratory drug consumption or other drug consumption and: asthma/COPD with anxiety/depression ('AC-AD'); asthma/COPD without anxiety/depression ('AC'); anxiety/depression without asthma/COPD ('AD'); neither anxiety/depression nor asthma/COPD ('NN'). Subjects who didn't use any drug were the reference category. Results: 80.1% of contacted subjects participated (n=977). Analyses concerned 903/977 subjects who filled in HADS questionnaire (mean age:56.5 yrs±18.0; 45.3% male). 7.0% of subjects had 'AC-AD', 27.8 % 'AC', 9.4% 'AD': 30.2% of subjects with 'AC-AD' used respiratory drugs compared to 21.1% of subjects with 'AC' and no subject with only 'AD'. Respiratory drug consumption was significantly associated with 'AC' (OR=12.14; 95% CI=5.56-26.52) and 'AC-AD' (OR=15.21; 95% CI=4.28-53.99). Use of respiratory drugs was also significantly associated with female gender (OR=2.37; 95% CI=1.22-4.60) and medical examination because of breathing problems/shortness of breath (OR=9.25; 95% CI=4.22-20.27). Moreover 'AC', 'AC-AD' and 'AD' were significantly associated with other drug consumption: OR=2.58 (95% CI=1.64-4.06), OR=3.46 (95% CI=1.25-9.51) and OR=2.42 (95% CI=1.33-4.42) respectively. Use of other drug was also significantly associated with age: 46-64 yrs (OR=2.59; 95% CI=1.56-4.31) and >=65 yrs (OR=8.41; 95% CI=4.84-14.60). (literal)
Prodotto di
Autore CNR

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
data.CNR.it